Effects of omeprazole in improving concurrent chemoradiotherapy efficacy in rectal cancer

Table 3 Differences in clinicopathological characteristics of non-eligible omeprazole users and eligible omeprazole users

Characteristics	Total	EOG		P value
		Non	Yes
Sex
Male	90	71	19	0.380
Female	35	25	10
Age(yr)
< 60	73	58	15	0.410
≥ 60	52	38	14
BMI
< 25	100	77	23	0.920
≥ 25	25	19	4
Tumor size (cm)
≤ 3	49	37	12	0.940
3-6	61	47	14
≥ 6	15	12	3
Tumor grade
1	28	22	6	0.960
2	88	67	21
3	9	7	2
cTNM
II	39	30	9	0.980
III	86	66	20
CEA (ng/mL)
< 5	62	45	17	0.390
≥ 5	58	46	12
CA19-9 (U/mL)
< 35	102	76	26	0.420
≥ 35	18	15	3
TGR
0	39	34	5	0.330
1	15	11	4
2	20	16	4
3	24	17	7
4	27	18	9
CRT efficacy
Poor	74	61	13	0.072
Good	51	35	16
ypTNM
ypcr	25	16	9	0.380
I	26	21	5
II	40	31	9
III	34	28	6
Adjuvant CT
No	21	14	7	0.230
Yes	104	82	22
Recurrence
No	97	66	26	0.025
Yes	28	30	3

EOG: Effective OME group; non-EOG: Non-effective OME group; BMI: Body mass index; TGR: Tumor regression grade; adjuvant CT: Adjuvant chemotherapy.